Forte Biosciences (FBRX) Liabilities and Shareholders Equity (2016 - 2026)

Forte Biosciences (FBRX) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $67.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 41.64% year-over-year to $67.2 million; the TTM figure through Mar 2026 stood at $354.9 million (up 131.88% YoY), while the FY2025 annual figure was $82.8 million, up 34.47% from the prior year.
• Liabilities and Shareholders Equity declined to $67.2 million in Q1 2026 per FBRX's latest filing, from $82.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $107.8 million in Q2 2025 and bottomed at $17.9 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $50.8 million across 5 years, with a median of $42.0 million in 2022.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity slumped 62.52% — and 2025, when it surged 441.01%.
• Forte Biosciences' Liabilities and Shareholders Equity stood at $42.0 million in 2022, then fell by 7.18% to $39.0 million in 2023, then jumped by 57.93% to $61.6 million in 2024, then surged by 34.47% to $82.8 million in 2025, then fell by 18.79% to $67.2 million in 2026.
• Business Quant data shows FBRX's Liabilities and Shareholders Equity at $67.2 million in Q1 2026, $82.8 million in Q4 2025, and $97.1 million in Q3 2025.